//fpnotebook.com/
Nimodipine
Aka: Nimodipine, Nymalize
- Indications
- Cerebral Vasospasm following Subarachnoid Hemorrhage (FDA Approved)
- Blood Pressure Control after Cerebrovascular Accident
- Contraindications
- Liver Failure
- Hypotension
- Mechanism
- Second Generation Dihydropyridine Calcium Channel Blocker
- Inhibits vascular Smooth Muscle contractility
- Pharmacokinetics
- Crosses the blood brain barrier (lipophilic)
- Safety
- Unknown safety in pregnancy
- Present in Breast Milk
- Dosing: Adult
- Started within 96 hours of event and continued for 21 days
- Standard Dose (including in impaired Renal Function)
- Nimodipine 60 mg orally or via Nasogastric Tube every 4 hours
- Reduced Dose (Cirrhosis)
- Nimodipine 30 mg orally or via Nasogastric Tube every 4 hours
- Precautions
- Do NOT use parenterally due to cardiovascular event risk (may be lethal)
- Monitor Blood Pressure
- Adverse Effects
- Hypotension
- Headache
- Flushing
- Palpitations
- Nausea
- Diarrhea
- References
- Spencer and LoVecchio (2021) Crit Dec Emerg Med 35(7): 32
- Liu (2011) CNS Neurol Disord Drug Targets 10(7):834-44 +PMID: 21999736 [PubMed]